Most women evaluated for angina have no obstructive coronary artery disease (ANOCA), yet many have persistent symptoms1, and the long-term burden of angina-related healthcare utilization remains poorly defined. Coronary microvascular dysfunction (CMD), reflected by impaired coronary flow velocity reserve (CFVR),...
L. Rytoft, N. Mygind, T. Holmager et al.· European Heart Journal· 0 citations
Women with angina and no obstructive coronary artery disease (ANOCA) remain at increased cardiovascular risk, likely in part driven by systemic inflammation and coronary microvascular dysfunction (CMD). Interleukin-6 (IL-6) is a key inflammatory mediator associated with cardiovascular events in the general popula...
R. Haahr, L. Rytoft, N. Mygind et al.· European Heart Journal· 0 citations
The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.
H. Caglar, T. Holmager, A. Kristensen et al.· European Heart Journal - Qua...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.